Section 271(e)(1) Safe Harbor Applies to Importation Regardless of Intent or Actual Use

April 18, 2024

Reading Time : 3 min

A divided panel of the Federal Circuit affirmed a district court’s grant of summary judgment of noninfringement, holding that importation of two product samples into the U.S. was reasonably related to obtaining FDA approval based on the particular facts of this case. In dissent, Judge Lourie disagreed, suggesting that summary judgment was not appropriate where factual disputes existed as to whether the importation was “solely” for purposes related to FDA approval.

At issue in this case was the importation of two sample heart valve systems. The accused infringer brought the samples into the U.S. in connection with a medical trade show. It was undisputed, however, that the samples were never shown at the trade show. It was also undisputed that the accused infringer never offered for sale or sold the samples. And in advance of the trade show, the accused infringer instructed its employees that they could not make offers for sale in the U.S. But the employees were permitted to make offers for other countries where the systems were already approved for human use. According to the accused infringer, it brought the samples to the U.S. trade show to identify potential clinicians for its premarket approval application who were known to attend the trade show. In support of this assertion, the accused infringer presented evidence that it started work on a premarket approval submission, began planning a “Landmark Trial” to include in future submissions to the FDA, contacted the FDA about the requirements for a premarket submission and retained a medical device consulting company to assist with its premarket submission.

Based on these facts, the district court found the accused infringer’s activities were protected by the Safe Harbor provision, and granted summary judgment of non-infringement. 

On appeal, the patentee argued the district court failed to apply an objective standard to the Safe Harbor and instead improperly relied on the accused infringer’s intent. The Federal Circuit rejected this argument, explaining that “the relevant inquiry is not why” the accused infringer imported the samples “or how” it used the samples, “but whether the act of importation was for a use reasonably related to submitting information to the FDA.” In view of the undisputed evidence that no offers for sale were made, the court held that no reasonably minded juror could have concluded the importation was “solely to support commercial sales, rather than to recruit clinical investigators.” According to the majority, “solely” as used in the Safe Harbor modifies uses and means, for each act of infringement, the safe harbor is available where the acts or uses that constitute infringement bear a reasonable relation to the development and submission of information to the FDA.

On this point, Judge Lourie dissented. In Judge Lourie’s view, the majority opinion and the Federal Circuit precedence on which it relies read the word “solely” out of the Safe Harbor. Judge Lourie believes that solely limits the application of the Safe Harbor to acts that have no purpose other than the development of information for the FDA. In other words, the Safe Harbor does not exist to protect acts that have a dual purpose, one of which is commercial. And here, factual disputes existed at least as to whether the accused infringer’s importation served a dual purpose—FDA approval and sales. Judge Lourie urged that consideration by the Federal Circuit en banc is warranted to consider the proper construction of the Safe Harbor provision.

Practice Tip: Parties who are actively developing products for which FDA approvals are required prior to commercial use should take care to ensure that any potential act of infringement preceding FDA approval is tied to the development of information that will be submitted to the FDA. Such activity is protected if it is reasonably related to an FDA submission; whereas activity that is solely commercial in nature is exempt from the Safe Harbor.  

Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd., No. 2022-1877, 2024 WL 1243032 (Fed. Cir. Mar. 25, 2024)

Share This Insight

Previous Entries

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 3, 2024

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

...

Read More

IP Newsflash

September 27, 2024

In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of a “person of ordinary skill in the art” of the asserted patents in order to opine on infringement, among other issues. This new bright-line test and the underlying rationale, however, raised several new questions regarding expert admissibility. SeeFederal Circuit: Narrow Definition of Skill in the Art Dooms Expert’s Testimony” and “Grappling With A Bright-Line Patent Expert Admissibility Test.” The Federal Circuit recently addressed one of those questions, namely whether an expert must have acquired the requisite level of skill as of the time of the invention or whether it is sufficient for an expert to acquire that knowledge at a later date.

...

Read More

IP Newsflash

September 23, 2024

The Director of the USPTO initiated sua sponte review of a PTAB panel’s decision to impose sanctions based on patentee’s conduct during IPR proceedings. The PTAB cancelled all of patentee’s claims, including those not unpatentable on the merits, after finding that patentee deliberately withheld data relevant to the patentability of the claims at issue. In her review, the Director addressed which regulations are implicated upon a party’s misconduct during AIA proceedings and addressed whether entry of judgment in the trial was an appropriate sanction.

...

Read More

IP Newsflash

September 18, 2024

The Western District of Texas granted a motion to stay a patent infringement lawsuit pending inter partes review not only because doing so would simplify the issues in the still-early litigation and reduce the burden on the parties, but also because the non-moving party failed to diligently file its lawsuit despite a protracted negotiations period.

...

Read More

IP Newsflash

September 16, 2024

The Federal Circuit dismissed an appeal from an inter partes review (“IPR”) final written decision for lack of standing where it found the appellant failed to provide evidence sufficient to show it suffered an injury in fact.

...

Read More

IP Newsflash

September 9, 2024

The Federal Circuit recently affirmed an ITC holding that the AIA’s § 102 on-sale bar applies to the sale of a product made according to a secret process when that sale occurs more than one year before the patent’s effective filing date. In so doing, the court confirmed that, despite changes to the text of § 102, the AIA did not undo long-settled pre-AIA precedent that the on-sale bar applies when, before the critical date, a party sells products secretly made using a patented process.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.